ocal anaesthesia and Bellovac ABT.
Completed
- Conditions
- total knee arthroplasty, retransfusion, local anesthesia
- Registration Number
- NL-OMON22267
- Lead Sponsor
- Medical Center Haaglanden, the Hague
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1. Patients must have pre-operative haemoglobin levels above 7.5 mmol/L;
2. Patients will be operated under spinal anaesthesia;
Exclusion Criteria
1. Patients with a major surgical procedure during the 12 weeks before the study-related operation;
2. Patients with documented allergy for the medication (ropivacaine, bupivacaine, NSAIDs, aminoacetophen or opiates) used in the study or any other local anaesthetic of the amino amide type;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ropivacaine will be quantified in patient serum (0, 3, 6 and 24 h after surgery) and in the blood-tissue fluid collected and filtered in the Bellovac ABT system in order to be able to calculate systemic exposure after reinfusion of the blood.
- Secondary Outcome Measures
Name Time Method VAS painscores.